13F

Stock

Neuphoria Therapeutics Inc.

NEUP · held by 19 managers

Reported value

$7M

Holders

19

+4 new · −7 exited

Holders’ est. mark

$245.5K

Price effect on 13 books still in the name

Largest holder

$3.56M

Lynx1 Capital Management LP

Notable conviction

Share of each notable manager’s 13F book.

Holder count by quarter

Who holds it

Notable only
InvestorSharesValueEst. markChange
Lynx1 Capital Management LP875.3K$3.56M$166.3KAdded$166.7K
AdvisorShares Investments LLC155.4K$632.3K$25.5KAdded$111.7K
Shay Capital LLC151K$614.6K$28.7KCut−$41.3K
Balyasny Asset Management L.P.142.2K$578.7KNew
VANGUARD CAPITAL MANAGEMENT LLC98.5K$401KHeld
Squadron Capital Management LLC76.7K$312.3KNew
GEODE CAPITAL MANAGEMENT, LLC52K$211.7K$3.29KAdded$144.5K
Ikarian Capital, LLC47.4K$193.1K$9.01KAdded$9.01K
VANGUARD FIDUCIARY TRUST CO33.6K$136.7KHeld
ADAR1 Capital Management, LLC30K$122.1K$5.7KAdded$5.7K
Citadel19.3K$78.7KNew
BOOTHBAY FUND MANAGEMENT, LLC14K$57K$2.66KAdded$2.66K
COMMONWEALTH EQUITY SERVICES, LLC11.2K$45.7K$2.13KAdded$2.19K
Merck & Co., Inc.10K$40.8K$1.91KAdded$1.91K
UBS Group AG2.32K$9.43K$315Added$3.02K
RHUMBLINE ADVISERS202$822$39Added$39
MORGAN STANLEY58$236$11Added$11
FNY Investment Advisers, LLC26.5K$107$5Added$5
Virtu Financial LLC12K$49New

Who left

Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.